Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Haven't seen any info on enrollments, but the trial did get moved from 'not started' to 'active' a few days ago which might indicate enrollment was progressing well:
https://discovery.dundee.ac.uk/en/projects/a-randomized-controlled-trial-of-sfx-01-to-improve-clinical-outco
Hopefully the new CEO will give us an update on this and the many other ongoing projects when he starts in the next week or two.
Is there any information on how many people have already received this?
This talks about first patient enrollment anticipated in July, so would have thought this should have made progress for enrolments in the last 3 months, but don't know if any info is available on enrolments.
https://www.lifearc.org/funding/covid-19-funding-2/sfx-01/
On and UP!!! Gla :-)
Heee ha
SNG's market cap rose by more than £300m on encouraging Phase 2 results for Covid-19, EVG's Phase 2 results for breast cancer were outstanding and "life changing for some patients", yet EVG's market cap sits at £15m.......and of course EVG also have SFX-01 in Phase 2/3 Covid-19 patient trials...!!!???? ;-)
Undoubted UPside potential!!! Gla ;-)
Market opportunity in ER+ metastatic breast cancer
Incidence of ER+ metastatic breast cancer is approximately 130,0001 in US and Europe
CDK4/6 inhibitors are now first line treatment, in combination with hormone therapy
Pfizer (Ibrance®/palbociclib), Novartis (Kisqali®/ribociclib) and Eli Lilly (Versenio®/abemaciclib ) are the key players with billion plus sales - sales forecast to reach c.$9bn by 2021/2
All patients become resistant to CDK4/6 inhibitors
Treatment options post CDK4/6 inhibitors are generally poorly tolerated – treatments which improve quality of life are needed in this terminal population
Potential of SFX-01 to be treatment of choice post CDK4/6 inhibitor failure, extending progression free survival with favourable side-effect profile.
http://evgen.com/wp-content/uploads/2020/07/EVG-Investor-Presentation-06Jul20-FINAL.pdf
ah i just read! 2021!
atb
any indications of results from the covid trial please?